CAR-T cell therapy research

This paper develops a 3D tumor microenvironment model to predict CAR-T therapy outcomes in solid tumors, finding that collagen density and metabolic competition are key determinants of efficacy.

This study shows dendritic cells enhance CAR T cell persistence in irradiated tumors by antigen-dressing and stimulating CAR T cells through chimeric receptors.

This study shows that combining GD2/OAcGD2-specific CAR and unmodified Vγ9Vδ2 T cells can overcome glioblastoma heterogeneity by targeting both PN and MES tumor states.

The paper applies T-cell receptor sequencing and epitope annotation tools to quality control and immune monitoring of TIL products by identifying tumor-specific clones and screening for off-cancer reactivity.

This paper introduces adCAR-T, an antigen-driven CAR T-cell expansion method that enables rapid, physiological CAR T cell programming without ex vivo manufacturing or lymphodepleting chemotherapy.

This study shows that tonic signaling in 4-1BB-based HER2 CAR-T cells affects manufacturability and performance, with context-dependent outcomes based on manufacturing conditions.

This study engineers CAR-T cells with HLA-G to evade immune rejection and demonstrates their tumor-inhibitory function in a humanized mouse model.

This paper develops a lipid nanoparticle strategy to enhance CAR-T cell persistence and antitumour efficacy in solid tumours by targeting primary lymphoid tissues.

This study shows that low-strength type I interferon signaling enhances CAR T-cell efficacy against B-cell lymphoma and leukemia without causing in vivo toxicity.

The paper reverse-engineers a TCR to reduce cross-reactivity while maintaining potency by reverting specific residues.

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

This study uses single-cell RNA sequencing to analyze EDA-CAR-T cell dynamics in the tumor microenvironment, revealing temporal reprogramming toward dysfunction and identifying immunosuppressive pathways that impair therapeutic efficacy in solid tumors.

This study identifies ZC3H12C as a target for improving T cell persistence and antitumor function in adoptive T cell therapy by disrupting its expression.

This study compares non-viral and lentiviral CAR-T cell manufacturing, finding comparable in vitro function but lower efficacy and increased exhaustion in non-viral CAR20-T cells in humanised mouse models.

The paper identifies ZC3H12C as a mediator of CAR-T cell dysfunction in solid tumors through an in vivo CRISPR screen and validates its role using single-cell RNA and ATAC-seq.

This study develops fully human B7-H3 CAR T cells using phage display, showing improved antitumor activity and reduced immune response in xenograft models.

This study develops allogeneic CRISPR-engineered CAR-T cells targeting GPC2 and GPC3, showing potent antitumor activity in solid tumors with repeated dosing and no toxicity.

This paper introduces a chimeric receptor (CARFcR) that combines CAR-T cell potency with antibody targeting, enabling effective cytotoxicity against both CD19+ and CD19- tumor cells using approved antibodies.

This study develops a dual CAR-T therapy targeting CD33 and TIM-3 in AML, showing improved specificity and efficacy through glycosylation-modulated TIM-3 recognition.

This study designs PD-1-targeting CAR-T-cells to reduce the HIV reservoir by depleting specific T-cell subpopulations in HIV-infected humanized mice.

This study uses molecular pixelation to profile CAR protein organization dynamics in CAR-T therapy, revealing co-localization network remodeling linked to clinical outcomes.

This study shows that inhibiting cathepsin B prevents CAR T cell fratricide and exhaustion by blocking trogocytosis, improving CAR T cell persistence and anti-tumor activity.

This paper develops a tumor organoid-CAF co-culture model to evaluate CAR-T drug efficacy by mimicking the tumor microenvironment's complexity.

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

This study develops GrB-CAR T cells targeting mHSP70 to eliminate CTCs and inhibit metastasis in solid tumors.

This paper modifies CAR-Vδ2 T cells to enhance their persistence and anti-tumor function by engineering IL-18 signaling and reducing activation-induced cell death.

This paper develops a method to create CAR-NK cells resistant to antigen shedding using circRNA and a novel scFv, showing comparable in vivo efficacy to lentiviral CAR-NK cells.

This paper validates a multicenter preclinical strategy for CAR T cells, demonstrating its feasibility in confirming CCR8 overexpression benefits across multiple centers.

This study shows that editing ULBP ligands reduces NK cell rejection of UCAR-T cells, improving their persistence and antitumor efficacy.

This study uses an in vivo CRISPR screen to identify genes that enhance CAR-T cell efficacy in a solid tumor model, finding that disrupting REGNASE-1, SOCS1, PTPN2, and P16/NK4A improves tumor eradication.